All In Biotech

Drug Trial Radar · NCT06237452

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 852 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

852

Planned (sponsor's estimate)

Start

May 20, 2024

Primary completion

Jun 2027

Study completion Oct 2027

Sponsor

Lead sponsor
Vedanta Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Feb 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE303 or matching placebo. The objectives and endpoints are identical for Stage 1 (recurrent CDI) and Stage 2 (high-risk primary CDI).

Conditions

  • Clostridium Difficile
  • Clostridium Difficile Infections
  • Clostridium Difficile Infection Recurrence
  • Clostridioides Difficile Infection
  • Clostridioides Difficile Infection Recurrence
  • CDI
  • C. Diff Infection
  • Recurrent Clostridium Difficile Infection
  • C.Difficile Diarrhea
  • Diarrhea Infectious

Interventions

  • VE303Biological

    VE303 is a live biotherapeutic product (LBP) consisting of 8 clonally derived, nonpathogenic, nontoxigenic, commensal bacteria strains manufactured under Good Manufacturing Practices (GMP) conditions.

  • PlaceboBiological

    Placebo capsules contain microcrystalline cellulose. Placebo capsules are visually identical to and not discernible from VE303 capsules. Placebo capsules will not contain any VE303 drug product.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CDI Recurrence Rate at Week 8Time frame: 8 weeks

Locations

215 sites in 24 countries. Site status is shown where the registry gives one.

  • Metro Infectious Disease Consultants

    Huntsville, Alabama · Recruiting

  • Advanced Gastroenterology, P.C.

    Chandler, Arizona · Withdrawn

  • Mayo Clinic Hospital

    Phoenix, Arizona · Withdrawn

  • GI Alliance

    Sun City, Arizona · Recruiting

  • Om Research, LLC

    Apple Valley, California · Withdrawn

  • Science 37 Inc (Remote/Home option)

    Culver City, California · Recruiting

  • Children's Hospital of Los Angeles

    Los Angeles, California · Recruiting

  • VA San Diego Healthcare System

    San Diego, California · Recruiting

  • North America Research Institute

    San Dimas, California · Withdrawn

  • Clinical Trials Management Services

    Thousand Oaks, California · Recruiting

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

    Torrance, California · Recruiting

  • Connecticut Clinical Research Institute

    Bristol, Connecticut · Recruiting

  • Medical Research Center of Connecticut

    Hamden, Connecticut · Recruiting

  • Hartford Hospital

    Hartford, Connecticut · Withdrawn

  • Gastro Florida

    Clearwater, Florida · Recruiting

  • Proactive Clinical Research, LLC

    Fort Lauderdale, Florida · Recruiting

  • Encore Borland-Groover Clinical Research

    Jacksonville, Florida · Recruiting

  • GI Pros Research

    Naples, Florida · Recruiting

  • Advanced Medical Research Center

    Port Orange, Florida · Recruiting

  • KM International Research Operation LLC

    Saint Cloud, Florida · Recruiting

  • James A. Haley Veterans' Hospital

    Tampa, Florida · Recruiting

  • International Center for Research

    Tampa, Florida · Recruiting

  • Summit Clinical Research, LLC

    Athens, Georgia · Recruiting

  • Emory University Hospital Midtown

    Atlanta, Georgia · Recruiting

  • Metro Infectious Disease Consultants

    Decatur, Georgia · Recruiting

  • Regional Infectious Diseases and Infusion Center, Inc.

    La Grange, Georgia · Withdrawn

  • Gastrointestinal Specialists of Georgia

    Marietta, Georgia · Recruiting

  • Snake River Research, PLLC

    Idaho Falls, Idaho · Recruiting

  • Metro Infectious Disease Consultants

    Burr Ridge, Illinois · Recruiting

  • NorthShore University Health System - Evanston Hospital

    Evanston, Illinois · Withdrawn

  • GI Alliance

    Gurnee, Illinois · Recruiting

  • Innovative Clinical Research Center, LLC (ICRC)

    Island Lake, Illinois · Withdrawn

  • Indiana University Health University Hospital

    Indianapolis, Indiana · Recruiting

  • Gastroenterology Health Partners

    New Albany, Indiana · Recruiting

  • Deaconess GI Specialty Center

    Newburgh, Indiana · Withdrawn

  • University of Kansas Medical Center

    Kansas City, Kansas · Recruiting

  • IDC Clinical Research, LLC

    Wichita, Kansas · Withdrawn

  • Gastroenterology Health Partners

    Louisville, Kentucky · Recruiting

  • Ochsner Clinic Foundation

    New Orleans, Louisiana · Recruiting

  • Johns Hopkins Hospital

    Baltimore, Maryland · Terminated

Showing 40 of 215 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.